NDAORALTABLET, EXTENDED RELEASE
Approved
May 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
KLOTRIX (potassium chloride) by Bristol Myers Squibb is clinical pharmacology the potassium ion is the principal intracellular cation of most body tissues. First approved in 1980.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KLOTRIX is an oral extended-release tablet containing potassium chloride, a critical electrolyte that maintains intracellular tonicity, nerve impulse transmission, and cardiac/skeletal muscle contraction. It treats hypokalemia (low potassium) caused by diuretic therapy, hyperaldosteronism, diabetic ketoacidosis, or gastrointestinal losses. The drug replaces depleted potassium by restoring normal plasma concentrations (3.5–5 mEq/L) through oral supplementation.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), signaling potential team downsizing or consolidation within Bristol Myers Squibb's portfolio.
Mechanism of Action
CLINICAL PHARMACOLOGY The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac,…
Worked on KLOTRIX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.